Rapport Therapeutics, Inc. Common Stock (RAPP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has a cash flow conversion efficiency ratio of -0.028x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.06 Million) by net assets ($471.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Rapport Therapeutics, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Rapport Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rapport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Changhai Compos Material
SHE:300196
|
0.028x |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
-0.113x |
|
Beijing Originwater Technology
SHE:300070
|
-0.006x |
|
Fidelis Insurance Holdings Limited
NYSE:FIHL
|
0.102x |
|
Pimco Dynamic Income Opportunities Fund
NYSE:PDO
|
0.276x |
|
Guangdong Advertising Co Ltd
SHE:002400
|
0.025x |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
0.056x |
|
Droneshield Ltd
AU:DRO
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Rapport Therapeutics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $484.65 Million | $-87.47 Million | -0.180x | +14.97% |
| 2024-12-31 | $305.43 Million | $-64.83 Million | -0.212x | -120.02% |
| 2023-12-31 | $-25.63 Million | $-27.18 Million | 1.060x | +737.94% |
| 2022-12-31 | $19.50 Million | $-3.24 Million | -0.166x | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more